Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

M. C. van Staveren; H. Jan Guchelaar; A. B. P. van Kuilenburg; H. Gelderblom; J. G. Maring

doi:https://doi.org/10.1038/tpj.2013.25

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

M. C. van Staveren, H. Jan Guchelaar, A. B. P. van Kuilenburg, H. Gelderblom, J. G. Maring

Research output: Contribution to journal › Review article › Academic › peer-review

75 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests

Original language	English
Pages (from-to)	389-395
Journal	pharmacogenomics journal
Volume	13
Issue number	5
DOIs	https://doi.org/10.1038/tpj.2013.25
Publication status	Published - 2013

Access to Document

https://doi.org/10.1038/tpj.2013.25

Cite this

@article{30a1bd322cd24fc3bb4b51faa5d6a41c,

title = "Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency",

abstract = "5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests",

author = "{van Staveren}, {M. C.} and {Jan Guchelaar}, H. and {van Kuilenburg}, {A. B. P.} and H. Gelderblom and Maring, {J. G.}",

year = "2013",

doi = "https://doi.org/10.1038/tpj.2013.25",

language = "English",

volume = "13",

pages = "389--395",

journal = "pharmacogenomics journal",

issn = "1470-269X",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

AU - van Staveren, M. C.

AU - Jan Guchelaar, H.

AU - van Kuilenburg, A. B. P.

AU - Gelderblom, H.

AU - Maring, J. G.

PY - 2013

Y1 - 2013

N2 - 5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests

AB - 5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests

U2 - https://doi.org/10.1038/tpj.2013.25

DO - https://doi.org/10.1038/tpj.2013.25

M3 - Review article

C2 - 23856855

SN - 1470-269X

VL - 13

SP - 389

EP - 395

JO - pharmacogenomics journal

JF - pharmacogenomics journal

IS - 5

ER -